The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice

Eur J Pharmacol. 2008 Apr 14;584(1):202-6. doi: 10.1016/j.ejphar.2008.01.028. Epub 2008 Feb 5.

Abstract

We investigated the effects of beta(3)-adrenoceptor agonist, 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316,243) in obese diabetic KKAy mice. Two weeks' subcutaneous administration of CL-316,243 reduced serum levels of glucose, insulin, triglyceride, free fatty acid and tumor necrosis factor-alpha (TNF-alpha), and increased adiponectin. Adiponectin, adiponectin receptors and beta(3)-adrenoceptor mRNA expressions were reduced in epididymal white adipose tissue in KKAy mice, and CL-316,243 recovered these mRNA expressions. Meanwhile, CL-316,243 suppressed the overexpressed mRNA level of TNF-alpha in both epididymal white adipose tissue and brown adipose tissue. These data suggest that the normalization of adiponectin, adiponectin receptors and TNF-alpha may result in the amelioration of obesity-induced insulin resistance.

MeSH terms

  • Adiponectin / blood
  • Adiponectin / genetics
  • Adiponectin / metabolism
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Adrenergic beta-3 Receptor Agonists*
  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / pharmacology*
  • Animals
  • Blood Glucose / drug effects
  • Body Weight
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / etiology
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / physiopathology
  • Dietary Fats / administration & dosage
  • Dioxoles / administration & dosage
  • Dioxoles / pharmacology*
  • Disease Models, Animal
  • Eating
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacology*
  • Injections, Subcutaneous
  • Insulin / blood
  • Insulin Resistance
  • Lipids / blood
  • Male
  • Mice
  • Obesity / complications
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Obesity / physiopathology
  • Receptors, Adiponectin / blood
  • Receptors, Adiponectin / genetics
  • Receptors, Adiponectin / metabolism*
  • Receptors, Adrenergic, beta-3 / genetics
  • Receptors, Adrenergic, beta-3 / metabolism
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • Adiponectin
  • Adipoq protein, mouse
  • Adrenergic beta-3 Receptor Agonists
  • Adrenergic beta-Agonists
  • Blood Glucose
  • Dietary Fats
  • Dioxoles
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • Receptors, Adiponectin
  • Receptors, Adrenergic, beta-3
  • Tumor Necrosis Factor-alpha
  • disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate